HIMS Stock: Price, Earnings History and SEC Filings
Hims & Hers Health, Inc. (HIMS) last traded at $27.68, down 6.71% on the latest session and down 7.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.10 against an analyst estimate of $-0.07, a miss of 42.9%.
$27.68 -6.71%
1 month-7.08%
52-week high$48.34
52-week low$13.74
Volume10.83M
ExchangeNYSE
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
HIMS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.10 | $-0.07 | -42.86% |
| Mar 2026 | May 11, 2026 | $-0.18 | $0.04 | -550.00% |
| Dec 2025 | Feb 23, 2026 | $0.07 | $0.02 | +250.00% |
| Sep 2025 | Nov 3, 2025 | $0.09 | $0.09 | +0.00% |
HIMS beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for HIMS
SEC filing data is not available right now. You can search for HIMS on SEC EDGAR.
HIMS news
- Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should KnowOct 29, 2026 · finance.yahoo.com
- Teladoc Soars 11% on Q3 Beat and Raised Outlook as “Insurance Revenue Exceeded Our Expectations”Oct 29, 2026 · tikr.com
- Eli Lilly Soars 5% as Mounjaro and Zepbound Demand Drives $5.5 Billion Guidance RaiseOct 29, 2026 · tikr.com
- Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics EasesOct 29, 2026 · 247wallst.com
- HIMS Stock Jumps 5% After HHS Temporarily Clears Compounding Of Six PeptidesOct 28, 2026 · stocktwits.com
- Hims Stock Surges After RFK Jr. Eases Access To Unapproved PeptidesOct 28, 2026 · finance.yahoo.com
- Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide CompoundingOct 28, 2026 · tikr.com
- Can Hims & Hers Stock Fall 30%?Oct 28, 2026 · trefis.com
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is a US-listed public company on NYSE.